Anika Therapeutics (ANIK) Common Equity (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Common Equity data on file, last reported at $133.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $133.9 million, down 9.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $133.9 million (down 9.77% YoY), and the FY2025 annual result was $143.5 million, down 6.83% from the prior year.
• Common Equity retreated to $133.9 million in Q1 2026 per ANIK's latest filing, from $143.5 million in the prior quarter.
• Over five years, Common Equity peaked at $286.2 million in Q2 2022 and troughed at $133.9 million in Q1 2026.
• A 5-year average of $214.7 million and a median of $210.3 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity grew 3.3% in 2022, then plunged 33.5% in 2024.
• A 5-year view of Common Equity shows it stood at $285.6 million in 2022, then retreated by 25.67% to $212.3 million in 2023, then dropped by 27.45% to $154.0 million in 2024, then dropped by 6.83% to $143.5 million in 2025, then slipped by 6.67% to $133.9 million in 2026.
• Business Quant data shows ANIK's Common Equity at $133.9 million in Q1 2026, $143.5 million in Q4 2025, and $146.8 million in Q3 2025.